Coronary computed tomographic angiography was associated with a lower 5-year mortality rate in patients with stable chest pain.

Surgical and transcatheter aortic valve replacement had a similar risk for adverse outcomes in patients with severe aortic stenosis, regardless of whether or not the patients had prior cardiac surgery.

Rivaroxaban was not superior to placebo for reducing the rate of death, MI, or stroke in patients with chronic heart failure.

Tafamidis was associated with reduced all-cause mortality and cardiovascular-related complications in patients with transthyretin amyloid cardiomyopathy.

Mortality benefits from atorvastatin- and amlodipine-based antihypertensive treatments extend beyond 10 years of treatment.

Ticagrelor without aspirin offered no additional benefits compared with conventional dual antiplatelet therapy in patients undergoing PCI for either CAD or ACS.

Net adverse cardiac events occurred in 15.2% of patients with radial access and 17.2% with femoral access while undergoing invasive therapies for acute coronary syndrome.

The new analysis included 19,134 of these patients and showed that there were 19% fewer deaths in patients initiated on NOACs compared to VKAs at the time of AF diagnosis.

For this double-blind, placebo-controlled study, researchers selected male patients ≥55 years and female patients ≥60 years with average cardiovascular risk and assigned them to enteric-coated aspirin 100mg (N=6270) or placebo (N=6276) once daily; the median follow-up time was 60 months.

In the CAMELLIA-TIMI 61 study, 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors were randomized to receive either lorcaserin 10mg twice daily or placebo.